摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。/ |5 ]+ T! e. R8 Z- O2 M \: b
关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
) l/ J2 J, x/ y E* \& R9 k
^) w1 p6 j5 u+ Z, ^8 x作者：来自澳大利亚
2 \# u: o, `* r" A8 l# H. z6 B来源：Haematologica. 2011.8.9.
3 t/ J1 p8 G D2 WDear Group,5 ?$ U! C9 I" ~" W; A3 V
- A: ?, [: z+ t- v0 y" HSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML L/ l0 L6 M1 a- T O
therapies. Here is a report from Australia on 3 patients who went off Sprycel) O6 i6 w% B; ^ s' z
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients- u0 m& [/ H3 r- q# r
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel& ?2 \- I% W' B3 X( y/ F. ]
does spike up the immune system so I hope more reports come out on this issue.( R; ~; o# H. Q6 R% G6 ~. R
$ i1 l. |$ g, r* p3 a8 \
The remarkable news about Sprycel cessation is that all 3 patients had failed
- W3 N5 G5 A0 i9 EGleevec and Sprycel was their second TKI so they had resistant disease. This is
. B. i: h# R+ D: w2 ~+ J. q& [different from the stopping Gleevec trial in France which only targets patients
" v' N* m0 K+ I5 E; Owho have done well on Gleevec.
' l& \$ g1 I% r% N: K' E; x
1 n( e7 I1 t& ^" z/ NHopefully, the doctors will report on a larger study and long-term to see if the
0 d$ R8 m: A6 f3 presponse off Sprycel is sustained.
% W' I' H+ A2 z { H O9 S1 ^9 b4 [. X2 @) b+ w# k3 e! k
Best Wishes,6 g4 y8 [6 n7 H9 I0 I
Anjana
7 d4 B) X: T2 E
/ m: Q5 V' e3 a: g1 T8 ?3 i+ q* R4 K& Y# d' [, W
6 c- f/ h z( |& UHaematologica. 2011 Aug 9. [Epub ahead of print]
' A% }5 G9 O g' C% QDurable complete molecular remission of chronic myeloid leukemia following7 D6 y/ _5 @' f/ {6 Z7 N
dasatinib cessation, despite adverse disease features.
0 b4 H! d% J: K0 ^/ W( tRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.( g+ x, m$ w H
Source
; a5 |( s# Z; xAdelaide, Australia;
, c% h# f. X/ ]8 t2 x! B, \# O2 Y; p( @
Abstract
, f" M0 \. a: \2 i1 }Patients with chronic myeloid leukemia, treated with imatinib, who have a
/ j$ J; a, ]( f3 Hdurable complete molecular response might remain in CMR after stopping
5 Z6 T( D2 Z/ }8 E$ ]$ ntreatment. Previous reports of patients stopping treatment in complete molecular: T: b% h' u+ g, S2 Z/ ^
response have included only patients with a good response to imatinib. We
; R( k4 @3 u+ u: Adescribe three patients with stable complete molecular response on dasatinib1 }) X" x! [0 k, @ Q, _ f6 ]
treatment following imatinib failure. Two of the three patients remain in
, d8 M0 X4 x+ M& ?" gcomplete molecular response more than 12 months after stopping dasatinib. In
: o, `- O' ~7 g% a1 J4 mthese two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to2 n, S5 r5 _" y) V' N
show that the leukemic clone remains detectable, as we have previously shown in
+ z6 w1 ?2 Q: L2 j9 h0 ^' yimatinib-treated patients. Dasatinib-associated immunological phenomena, such as
2 b2 ?# f* B; f$ y9 Gthe emergence of clonal T cell populations, were observed both in one patient9 [: r6 S U0 R; H
who relapsed and in one patient in remission. Our results suggest that the. C5 s- N% { F
characteristics of complete molecular response on dasatinib treatment may be
# p4 ~# Q& T' `similar to that achieved with imatinib, at least in patients with adverse: p4 K) e" U: [6 O4 L; l
disease features.
7 @4 k( {$ Z2 Q8 K% o3 F |
显身卡
